22
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Renal drug transporters and their significance in drug–drug interactions

      review-article
      , *
      Acta Pharmaceutica Sinica. B
      Elsevier
      ABC, ATP-binding cassette, ATP, adenosine triphosphate, AUC, area under the plasma concentration curve, BBB, blood–brain barrier, Cmax, maximum plasma concentration, CHO, Chinese hamster ovary, CL, plasma clearance, CLR, renal clearance, DDIs, drug–drug interactions, fe, fraction of the absorbed dose excreted unchanged in urine, FDA, U.S. Food and Drug Administration, GSH, glutathione, HEK, human embryonic kidney, IC50, half maximal inhibitory concentration, ITC, International Transporter Consortium, Ki, inhibitory constant, MATE, multidrug and toxin extrusion protein, MPP+, 1-methyl-4-phenylpyridimium, MRP, multidrug resistance-associated protein, MSD, membrane-spanning domain, MW, molecular weight, NBD, nucleotide-binding domain, NME, new molecular entity, NSAID, non-steroidal anti-inflammatory drugs, OA, organic anion, OAT or Oat, organic anion transporters, OATP or Oatp, organic anion-transporting peptide, OC, organic cation, OCT or Oct, organic cation transporter, OCTN, Organic zwitterions/cation transporters, PAH, p-aminohippurate, P-gp, P-glycoprotein, SLC, solute carrier, SNP, single-nucleotide polymorphism, TMD, transmembrane domain, TEA, tetraethylammonium, URAT, urate transporter, Renal drug transporters, Drug–drug interactions, Organic cations, Organic anions, Nephrotoxicity

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The kidney is a vital organ for the elimination of therapeutic drugs and their metabolites. Renal drug transporters, which are primarily located in the renal proximal tubules, play an important role in tubular secretion and reabsorption of drug molecules in the kidney. Tubular secretion is characterized by high clearance capacities, broad substrate specificities, and distinct charge selectivity for organic cations and anions. In the past two decades, substantial progress has been made in understanding the roles of transporters in drug disposition, efficacy, toxicity and drug–drug interactions (DDIs). In the kidney, several transporters are involved in renal handling of organic cation (OC) and organic anion (OA) drugs. These transporters are increasingly recognized as the target for clinically significant DDIs. This review focuses on the functional characteristics of major human renal drug transporters and their involvement in clinically significant DDIs.

          Graphical abstract

          Renal drug transporters, expressed in the basolateral and apical membrane of renal proximal tubules, play an important role in tubular secretion and reabsorption of drug molecules in the kidney. These transporters are increasingly recognized as the target for clinically significant drug–drug interactions.

          Related collections

          Most cited references115

          • Record: found
          • Abstract: found
          • Article: not found

          Membrane transporters in drug development.

          Membrane transporters can be major determinants of the pharmacokinetic, safety and efficacy profiles of drugs. This presents several key questions for drug development, including which transporters are clinically important in drug absorption and disposition, and which in vitro methods are suitable for studying drug interactions with these transporters. In addition, what criteria should trigger follow-up clinical studies, and which clinical studies should be conducted if needed. In this article, we provide the recommendations of the International Transporter Consortium on these issues, and present decision trees that are intended to help guide clinical studies on the currently recognized most important drug transporter interactions. The recommendations are generally intended to support clinical development and filing of a new drug application. Overall, it is advised that the timing of transporter investigations should be driven by efficacy, safety and clinical trial enrolment questions (for example, exclusion and inclusion criteria), as well as a need for further understanding of the absorption, distribution, metabolism and excretion properties of the drug molecule, and information required for drug labelling.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Molecular identification of a renal urate anion exchanger that regulates blood urate levels.

            Urate, a naturally occurring product of purine metabolism, is a scavenger of biological oxidants implicated in numerous disease processes, as demonstrated by its capacity of neuroprotection. It is present at higher levels in human blood (200 500 microM) than in other mammals, because humans have an effective renal urate reabsorption system, despite their evolutionary loss of hepatic uricase by mutational silencing. The molecular basis for urate handling in the human kidney remains unclear because of difficulties in understanding diverse urate transport systems and species differences. Here we identify the long-hypothesized urate transporter in the human kidney (URAT1, encoded by SLC22A12), a urate anion exchanger regulating blood urate levels and targeted by uricosuric and antiuricosuric agents (which affect excretion of uric acid). Moreover, we provide evidence that patients with idiopathic renal hypouricaemia (lack of blood uric acid) have defects in SLC22A12. Identification of URAT1 should provide insights into the nature of urate homeostasis, as well as lead to the development of better agents against hyperuricaemia, a disadvantage concomitant with human evolution.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview.

              Active drug efflux transporters of the ATP binding cassette (ABC)-containing family of proteins have a major impact on the pharmacological behavior of most of the drugs in use today. Pharmacological properties affected by ABC transporters include the oral bioavailability, hepatobiliary, direct intestinal, and urinary excretion of drugs and drug-metabolites and -conjugates. Moreover, the penetration of drugs into a range of important pharmacological sanctuaries, such as brain, testis, and fetus, and the penetration into specific cell- and tissue compartments can be extensively limited by ABC transporters. These interactions with ABC transporters determine to a large extent the clinical usefulness, side effects and toxicity risks of drugs. Many other xenotoxins, (pre-)carcinogens and endogenous compounds are also influenced by the ABC transporters, with corresponding consequences for the well-being of the individual. We aim to provide an overview of properties of the mammalian ABC transporters known to mediate significant transport of clinically relevant drugs.
                Bookmark

                Author and article information

                Contributors
                Journal
                Acta Pharm Sin B
                Acta Pharm Sin B
                Acta Pharmaceutica Sinica. B
                Elsevier
                2211-3835
                2211-3843
                09 August 2016
                September 2016
                09 August 2016
                : 6
                : 5
                : 363-373
                Affiliations
                [0005]Department of Pharmaceutics, University of Washington, Seattle, WA 98195-7610, USA
                Author notes
                [* ]Corresponding author at: Department of Pharmaceutics, University of Washington, H272J Health Sciences Building, Seattle, WA 98195-7610, USA. Tel.: +1 206 221 6561; fax: +1 206 543 3204 jowang@ 123456uw.edu
                Article
                S2211-3835(16)30152-6
                10.1016/j.apsb.2016.07.013
                5045553
                27709005
                19d119c0-6cc5-45b2-ad99-77653433f636
                © 2016 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.

                This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

                History
                : 27 April 2016
                : 30 June 2016
                : 7 July 2016
                Categories
                Review

                abc, atp-binding cassette,atp, adenosine triphosphate,auc, area under the plasma concentration curve,bbb, blood–brain barrier,cmax, maximum plasma concentration,cho, chinese hamster ovary,cl, plasma clearance,clr, renal clearance,ddis, drug–drug interactions,fe, fraction of the absorbed dose excreted unchanged in urine,fda, u.s. food and drug administration,gsh, glutathione,hek, human embryonic kidney,ic50, half maximal inhibitory concentration,itc, international transporter consortium,ki, inhibitory constant,mate, multidrug and toxin extrusion protein,mpp+, 1-methyl-4-phenylpyridimium,mrp, multidrug resistance-associated protein,msd, membrane-spanning domain,mw, molecular weight,nbd, nucleotide-binding domain,nme, new molecular entity,nsaid, non-steroidal anti-inflammatory drugs,oa, organic anion,oat or oat, organic anion transporters,oatp or oatp, organic anion-transporting peptide,oc, organic cation,oct or oct, organic cation transporter,octn, organic zwitterions/cation transporters,pah, p-aminohippurate,p-gp, p-glycoprotein,slc, solute carrier,snp, single-nucleotide polymorphism,tmd, transmembrane domain,tea, tetraethylammonium,urat, urate transporter,renal drug transporters,drug–drug interactions,organic cations,organic anions,nephrotoxicity

                Comments

                Comment on this article